Erwinase: Clinical Trials

10 trials of Erwinase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 210Recruiting 4, Terminated 2, Active not recruiting 1, Completed 1, Suspended 1, Withdrawn 1

Follow Erwinase: new trials by email Literature Review of Erwinase trials Research Report on Erwinase

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Phase 2SuspendedUniversity of Washington302026-05-082026-09-29
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Phase 2RecruitingCity of Hope Medical Center532025-10-102026-10-13
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)1532025-06-052026-10-27
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)4612020-12-172026-11-12
Ma-Spore ALL 2020 Study
Prednisolone, Dexamethasone, Vincristine - B Lymphoblastic Leukemia
Phase 2RecruitingNational University Hospital, Singapore5002020-03-042024-03-28
AflacLL1901 (CHOA-AML)
Cytarabine, Daunorubicin, Erwinase - Acute Myeloid Leukemia, AML, Childhood
Phase 2TerminatedEmory University82020-01-242022-06-15
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Fludarabine, Cytarabine, Erwinase - Hematologic Malignancy
Phase 2WithdrawnM.D. Anderson Cancer Center2018-05-012018-06-26
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 2Active not recruitingChildren's Oncology Group802017-06-192026-10-01
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Bortezomib, Vorinostat, Mitoxantrone - Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia
Phase 2TerminatedSt. Jude Children's Research Hospital122015-04-142018-03-07
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
Kidrolase, Methotrexate, Dexamethasone - Lymphoma, Non-Hodgkin
Phase 2CompletedUniversity Hospital, Limoges402006-02-012013-02-28

Conditions studied

Burkitt Lymphoma (6)  ·  Leukemia, Biphenotypic, Acute (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Lymphoma (2)  ·  Down Syndrome (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Prolymphocytic (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Children's Oncology Group (1)  ·  City of Hope Medical Center (1)  ·  Emory University (1)  ·  M.D. Anderson Cancer Center (1)  ·  National University Hospital, Singapore (1)  ·  St. Jude Children's Research Hospital (1)  ·  University Hospital, Limoges (1)  ·  University of Washington (1)

Countries

United States (7)  ·  Puerto Rico (3)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Malaysia (1)  ·  Singapore (1)

Top investigators

Allen Eng Juh Yeoh, MBBS (1)  ·  Erin H Breese (1)  ·  Himalee Sabnis, MD (1)  ·  Ibrahim Aldoss (1)  ·  Maureen M O'Brien (1)  ·  Ryan D. Cassaday, MD (1)  ·  Stacy L Cooper (1)  ·  Tanja A. Gruber, MD, PhD (1)  ·  Tapan Kadia, MD (1)

Results publications

PMID 35622074, PMID 41671463, PMID 21123825, PMID 32683126, PMID 35007127

NIH funding

U10CA180886 (3), 2019 (1), P30CA033572 (1)